Presentation is loading. Please wait.

Presentation is loading. Please wait.

Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen–induced rhinoconjunctivitis 

Published byAgnar Kristoffersen Modified over 5 years ago

Similar presentations

Presentation on theme: "Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen–induced rhinoconjunctivitis "— Presentation transcript:

1 Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen–induced rhinoconjunctivitis  Alain Didier, MD, Margitta Worm, MD, Friedrich Horak, MD, Gordon Sussman, MD, Olivier de Beaumont, MD, Martine Le Gall, Michel Melac, MD, Hans-Jorgen Malling, MD  Journal of Allergy and Clinical Immunology  Volume 128, Issue 3, Pages (September 2011) DOI: /j.jaci Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Study design. The circled R represents randomization to the 3 treatment arms. The actual time of the pollen season in each year is represented by the shaded bar. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Subject disposition during the 3 treatment years. FAS, Full analysis set (only for year 3). Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Most common (≥5%) treatment-related adverse events by intensity: incidence for seasons 1 to 3. Treatment-related adverse events are those considered by the investigator to be at least possibly related to the study treatment. TEAEs are events starting on or after the first administration at each treatment period, including the days of first and last administration of the investigational product. Adverse events are presented separately for the groups having received 2 or 4 months of active treatment and the placebo group. The 2-month treatment group had a shorter preseasonal treatment period, and these patients received placebo for the 2 months before the start of their active treatment; therefore they are presented separately as a 2-month placebo period and a 2-month active period. The placebo group used for efficacy comparisons received placebo during the entire 4 months before and then during the pollen season and is indicated for safety as 4 months of placebo. AC, Active treatment; PL, placebo. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen–induced rhinoconjunctivitis "

Similar presentations

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

D-dimer: A biomarker for antihistamine-resistant chronic urticaria
The Journal of Allergy and Clinical Immunology: In Practice

The Journal of Allergy and Clinical Immunology: In Practice
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Allergen immunotherapy: A practice parameter third update

Allergen immunotherapy: A practice parameter third update
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.
Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,
Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,
Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis  Alain Didier, MD,

Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis  Alain Didier, MD,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,
Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.
Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study  Karoline Krause, MD, Athanasios Tsianakas,

Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study  Karoline Krause, MD, Athanasios Tsianakas,
David A. Khan, MD  Journal of Allergy and Clinical Immunology 

David A. Khan, MD  Journal of Allergy and Clinical Immunology 
Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32  Verena Niederberger, MD, Angela Neubauer, PhD,

Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32  Verena Niederberger, MD, Angela Neubauer, PhD,
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Similar presentations

Ads by Google